I think is is way to early for a takeover at a reasonable share price that the shareholders would accept.
I am thinking that if the FDA has had visibility of the PMS Phase 2 results and they have similar efficacy as the pre-clinical mouse studies, then I am wondering if the FDA may have suggested a fast path for NNZ-2591 to get to PMS patients asap / quicker than planned. I am hoping this will be discussed on Monday as they results are announced.
Ann: Trading Halt, page-261
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.62 |
Change
-0.240(1.15%) |
Mkt cap ! $2.635B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $20.62 | $20.26 | $4.698M | 229.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 221 | $20.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.62 | 1553 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |